COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry

Study Purpose:

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and can complicate the clinical course as COVID-19 could lead to respiratory failure and need for intubation. We intend that this registry will guide our understanding of how COVID-19 affects patients with ALS.

Study Status:

Not recruiting

Disease:

Covid19 , Amyotrophic Lateral Sclerosis

Study Type:

Observational [Patient Registry]

Type of Intervention:

N/A

Intervention Name:

N/A

Placebo:

N/A

Phase:

N/A

Study Chair(s)/Principal Investigator(s):

Urvi Desai, MD, Neurologist/ MDA Director

Clinicaltrials.gov ID:

NCT04559009

Neals Affiliated?

No

Coordinating Center Contact Information

Full Study Summary: